

Diffuse Large B-cell Lymphoma (DLBCL) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/DBAA07577AE1EN.html>

Date: May 2024

Pages: 132

Price: US\$ 6,499.00 (Single User License)

ID: DBAA07577AE1EN

Abstracts

The 7 major Diffuse Large B-cell Lymphoma (DLBCL) markets reached a value of US\$ 3,907.8 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 5,257.7 Million by 2034, exhibiting a growth rate (CAGR) of 2.7% during 2024-2034.

Diffuse Large B-cell Lymphoma (DLBCL) market is currently driven by factors such as a rising patient pool, improving diagnosis and drug treatment rates, an increase in the geriatric population and rising safety and efficacy of current and emerging therapies, etc. Diffuse Large B-Cell Lymphoma, a form of non-Hodgkin lymphoma, represents the most common blood cancer. Lymphomas develop when immune cells, known as B lymphocytes, grow and multiply in an uncontrolled way. DLBCL develops mostly in adults and is a rapidly-growing (aggressive) lymphoma. It can begin in the lymph nodes or outside of the lymphatic system in the gastrointestinal tract, testes, thyroid, skin, breast, bone, or brain. Usually, the first symptoms of DLBCL is a painless swelling in the neck, armpit, abdomen, or groin caused by enlarged lymph nodes. This swelling can also be painful for some people. Other symptoms of DLBCL may include night sweats, unexplained fevers, and a loss in weight. DLBCL can occur at any age, however, it is generally rare in children and is more common in older people. Most people diagnosed with DLBCL are usually 60 or over. Furthermore, DLBCL affects slightly more males than females. Other risk factors include family history, certain infections, weakened immune system, obesity, exposure to certain chemicals, etc.

IMARC Group's new report "Diffuse Large B-cell Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast" provides an exhaustive analysis of the Diffuse Large B-cell Lymphoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The report

provides an in-depth understanding of current and future landscape of the Diffuse Large B-cell Lymphoma market. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Diffuse Large B-cell Lymphoma across the seven major markets. According to the report the United States has the largest patient pool for Diffuse Large B-cell Lymphoma and also represents the largest market for Diffuse Large B-cell Lymphoma treatment. Furthermore, the current Diffuse Large B-cell Lymphoma treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Diffuse Large B-cell Lymphoma market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

Analysis Covered Across Each Country

Historical, Current and Future Epidemiology Scenario

Historical, Current and Future Performance of the Diffuse Large B-cell Lymphoma Market

Historical, Current and Future Performance of Various Therapeutic Categories in the Diffuse Large B-cell Lymphoma Market

Sales of Various Drugs Across the Diffuse Large B-cell Lymphoma Market

Reimbursement Scenario in the Diffuse Large B-cell Lymphoma Market

Competitive Landscape:

This report also provides a detailed analysis of the current Diffuse Large B-cell Lymphoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

How has the Diffuse Large B-cell Lymphoma market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to be in 2034?

What was the country-wise size of the Diffuse Large B-cell Lymphoma market across the seven major markets in 2023 and how will it look like in 2034?

What is the growth rate of the Diffuse Large B-cell Lymphoma market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the Diffuse Large B-cell Lymphoma market?

Epidemiology Insights

What is the size of the Diffuse Large B-cell Lymphoma patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) of Diffuse Large B-cell Lymphoma across the seven major markets?

What are the key factors driving the epidemiological trend of Diffuse Large B-cell

Lymphoma?

What will be the growth rate of Diffuse Large B-cell Lymphoma patients across the seven major markets?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed Diffuse Large B-cell Lymphoma drugs and what are their market performance?

What are the key pipeline Diffuse Large B-cell Lymphoma drugs and how are they expected to perform in the coming years?

How safe are the current marketed Diffuse Large B-cell Lymphoma drugs and what are their efficacies?

How safe are the late-stage pipeline Diffuse Large B-cell Lymphoma drugs and what are their efficacies?

What are the current treatment guidelines for Diffuse Large B-cell Lymphoma drugs across the seven major markets?

Who are the key companies in the Diffuse Large B-cell Lymphoma market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Diffuse Large B-cell Lymphoma market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 DIFFUSE LARGE B-CELL LYMPHOMA - INTRODUCTION

- 4.1 Overview
- 4.2 Epidemiology (?2018-2023?) and Forecast (?2024-2034?)
- 4.3 Market Overview (?2018-2023?) and Forecast (?2024-2034?)
- 4.4 Competitive Intelligence

5 DIFFUSE LARGE B-CELL LYMPHOMA - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 DIFFUSE LARGE B-CELL LYMPHOMA - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (?2018-2023?)
 - 7.2.2 Epidemiology Forecast (?2024-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (?2018-2023?)
 - 7.3.2 Epidemiology Forecast (?2024-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (?2018-2023?)
 - 7.4.2 Epidemiology Forecast (?2024-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (?2018-2023?)
 - 7.5.2 Epidemiology Forecast (?2024-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (?2018-2023?)
 - 7.6.2 Epidemiology Forecast (?2024-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (?2018-2023?)
 - 7.7.2 Epidemiology Forecast (?2024-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (?2018-2023?)
 - 7.8.2 Epidemiology Forecast (?2024-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (?2018-2023?)
 - 7.9.2 Epidemiology Forecast (?2024-2034?)

8 DIFFUSE LARGE B-CELL LYMPHOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Diffuse Large B-cell Lymphoma Guidelines, Management and Treatment
- 8.2 Diffuse Large B-cell Lymphoma Treatment Algorithm

9 DIFFUSE LARGE B-CELL LYMPHOMA - UNMET NEEDS

10 DIFFUSE LARGE B-CELL LYMPHOMA - KEY ENDPOINTS OF TREATMENT

11 DIFFUSE LARGE B-CELL LYMPHOMA - MARKETING PRODUCTS

- 11.1 List of Diffuse Large B-cell Lymphoma Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Drug Name - Company Name

- 11.1.1.1 Drug Overview
- 11.1.1.2 Mechanism of Action
- 11.1.1.3 Regulatory Status
- 11.1.1.4 Clinical Trial Results
- 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 DIFFUSE LARGE B-CELL LYMPHOMA - PIPELINE PRODUCTS

12.1 List of Diffuse Large B-cell Lymphoma Pipeline Drugs Across the Top 7 Markets

- 12.1.1 Drug Name - Company Name
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Sales Outlook

Kindly note that the complete list of pipeline drugs has been provided in the report.

13 DIFFUSE LARGE B-CELL LYMPHOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14 DIFFUSE LARGE B-CELL LYMPHOMA - MARKET SCENARIO

- 14.1 Market Scenario - Key Insights
- 14.2 Market Scenario - Top 7 Markets
 - 14.2.1 Diffuse Large B-cell Lymphoma - Market Size
 - 14.2.1.1 Market Size (?2018-2023?)
 - 14.2.1.2 Market Forecast (?2024-2034?)
 - 14.2.2 Diffuse Large B-cell Lymphoma - Market Size by Therapies
 - 14.2.2.1 Market Size by Therapies (?2018-2023?)
 - 14.2.2.2 Market Forecast by Therapies (?2024-2034?)
- 14.3 Market Scenario - United States
 - 14.3.1 Diffuse Large B-cell Lymphoma - Market Size
 - 14.3.1.1 Market Size (?2018-2023?)
 - 14.3.1.2 Market Forecast (?2024-2034?)
 - 14.3.2 Diffuse Large B-cell Lymphoma - Market Size by Therapies
 - 14.3.2.1 Market Size by Therapies (?2018-2023?)
 - 14.3.2.2 Market Forecast by Therapies (?2024-2034?)
 - 14.3.3 Diffuse Large B-cell Lymphoma - Access and Reimbursement Overview

14.4 Market Scenario - Germany

14.4.1 Diffuse Large B-cell Lymphoma - Market Size

14.4.1.1 Market Size (?2018-2023?)

14.4.1.2 Market Forecast (?2024-2034?)

14.4.2 Diffuse Large B-cell Lymphoma - Market Size by Therapies

14.4.2.1 Market Size by Therapies (?2018-2023?)

14.4.2.2 Market Forecast by Therapies (?2024-2034?)

14.4.3 Diffuse Large B-cell Lymphoma - Access and Reimbursement Overview

14.5 Market Scenario - France

14.5.1 Diffuse Large B-cell Lymphoma - Market Size

14.5.1.1 Market Size (?2018-2023?)

14.5.1.2 Market Forecast (?2024-2034?)

14.5.2 Diffuse Large B-cell Lymphoma - Market Size by Therapies

14.5.2.1 Market Size by Therapies (?2018-2023?)

14.5.2.2 Market Forecast by Therapies (?2024-2034?)

14.5.3 Diffuse Large B-cell Lymphoma - Access and Reimbursement Overview

14.6 Market Scenario - United Kingdom

14.6.1 Diffuse Large B-cell Lymphoma - Market Size

14.6.1.1 Market Size (?2018-2023?)

14.6.1.2 Market Forecast (?2024-2034?)

14.6.2 Diffuse Large B-cell Lymphoma - Market Size by Therapies

14.6.2.1 Market Size by Therapies (?2018-2023?)

14.6.2.2 Market Forecast by Therapies (?2024-2034?)

14.6.3 Diffuse Large B-cell Lymphoma - Access and Reimbursement Overview

14.7 Market Scenario - Italy

14.7.1 Diffuse Large B-cell Lymphoma - Market Size

14.7.1.1 Market Size (?2018-2023?)

14.7.1.2 Market Forecast (?2024-2034?)

14.7.2 Diffuse Large B-cell Lymphoma - Market Size by Therapies

14.7.2.1 Market Size by Therapies (?2018-2023?)

14.7.2.2 Market Forecast by Therapies (?2024-2034?)

14.7.3 Diffuse Large B-cell Lymphoma - Access and Reimbursement Overview

14.8 Market Scenario - Spain

14.8.1 Diffuse Large B-cell Lymphoma - Market Size

14.8.1.1 Market Size (?2018-2023?)

14.8.1.2 Market Forecast (?2024-2034?)

14.8.2 Diffuse Large B-cell Lymphoma - Market Size by Therapies

14.8.2.1 Market Size by Therapies (?2018-2023?)

14.8.2.2 Market Forecast by Therapies (?2024-2034?)

- 14.8.3 Diffuse Large B-cell Lymphoma - Access and Reimbursement Overview
- 14.9 Market Scenario - Japan
 - 14.9.1 Diffuse Large B-cell Lymphoma - Market Size
 - 14.9.1.1 Market Size (?2018-2023?)
 - 14.9.1.2 Market Forecast (?2024-2034?)
 - 14.9.2 Diffuse Large B-cell Lymphoma - Market Size by Therapies
 - 14.9.2.1 Market Size by Therapies (?2018-2023?)
 - 14.9.2.2 Market Forecast by Therapies (?2024-2034?)
 - 14.9.3 Diffuse Large B-cell Lymphoma - Access and Reimbursement Overview

15 DIFFUSE LARGE B-CELL LYMPHOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

16 DIFFUSE LARGE B-CELL LYMPHOMA MARKET - SWOT ANALYSIS

- 16.1 Strengths
- 16.2 Weaknesses
- 16.3 Opportunities
- 16.4 Threats

17 APPENDIX

I would like to order

Product name: Diffuse Large B-cell Lymphoma (DLBCL) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/DBAA07577AE1EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DBAA07577AE1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

